| Dr Julius Kolawole Adebisi, MD | |
|
401 S Main St, Suite C7, Alpharetta, GA 30009-1974 | |
| (678) 319-9901 | |
| (678) 319-9902 |
| Full Name | Dr Julius Kolawole Adebisi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 35 Years |
| Location | 401 S Main St, Alpharetta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730127713 | NPI | - | NPPES |
| 390122159B | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 058939 (Georgia) | Secondary |
| 261QP2300X | Clinic/center - Primary Care | 058939 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellstar North Fulton Hospital | Roswell, GA | Hospital |
| Entity Name | Chestatee Emergency Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366474777 PECOS PAC ID: 5395657514 Enrollment ID: O20031105000156 |
News Archive
Nearly a billion years ago, bacteria evolved an insidious means of infecting their hosts - a syringe-like mechanism able to inject cells with stealthy hijacker molecules. These molecules, called virulence factors, play a sophisticated game of mimicry, imitating many of the cells' normal activities but ultimately co-opting them to serve the bacteria's needs.
More than 2 percent of all emergency department visits are now related to nontraumatic dental conditions, according to a study by researchers at Stanford University, the University of California-San Francisco, Truven Health Analytics and the federal Agency for Healthcare Research and Quality.
Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.
In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
› Verified 9 days ago
| Entity Name | Piedmont Hospitalist Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548219660 PECOS PAC ID: 1951299163 Enrollment ID: O20040309000820 |
News Archive
Nearly a billion years ago, bacteria evolved an insidious means of infecting their hosts - a syringe-like mechanism able to inject cells with stealthy hijacker molecules. These molecules, called virulence factors, play a sophisticated game of mimicry, imitating many of the cells' normal activities but ultimately co-opting them to serve the bacteria's needs.
More than 2 percent of all emergency department visits are now related to nontraumatic dental conditions, according to a study by researchers at Stanford University, the University of California-San Francisco, Truven Health Analytics and the federal Agency for Healthcare Research and Quality.
Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.
In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
› Verified 9 days ago
| Entity Name | Erx Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760823082 PECOS PAC ID: 9335037571 Enrollment ID: O20130930000326 |
News Archive
Nearly a billion years ago, bacteria evolved an insidious means of infecting their hosts - a syringe-like mechanism able to inject cells with stealthy hijacker molecules. These molecules, called virulence factors, play a sophisticated game of mimicry, imitating many of the cells' normal activities but ultimately co-opting them to serve the bacteria's needs.
More than 2 percent of all emergency department visits are now related to nontraumatic dental conditions, according to a study by researchers at Stanford University, the University of California-San Francisco, Truven Health Analytics and the federal Agency for Healthcare Research and Quality.
Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.
In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
› Verified 9 days ago
| Entity Name | Houston County Emergency Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013338193 PECOS PAC ID: 2264663756 Enrollment ID: O20140326001461 |
News Archive
Nearly a billion years ago, bacteria evolved an insidious means of infecting their hosts - a syringe-like mechanism able to inject cells with stealthy hijacker molecules. These molecules, called virulence factors, play a sophisticated game of mimicry, imitating many of the cells' normal activities but ultimately co-opting them to serve the bacteria's needs.
More than 2 percent of all emergency department visits are now related to nontraumatic dental conditions, according to a study by researchers at Stanford University, the University of California-San Francisco, Truven Health Analytics and the federal Agency for Healthcare Research and Quality.
Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.
In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
› Verified 9 days ago
| Entity Name | Spectrum Internal Medicine, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437576659 PECOS PAC ID: 4688895741 Enrollment ID: O20141015000971 |
News Archive
Nearly a billion years ago, bacteria evolved an insidious means of infecting their hosts - a syringe-like mechanism able to inject cells with stealthy hijacker molecules. These molecules, called virulence factors, play a sophisticated game of mimicry, imitating many of the cells' normal activities but ultimately co-opting them to serve the bacteria's needs.
More than 2 percent of all emergency department visits are now related to nontraumatic dental conditions, according to a study by researchers at Stanford University, the University of California-San Francisco, Truven Health Analytics and the federal Agency for Healthcare Research and Quality.
Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.
In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
› Verified 9 days ago
| Entity Name | Medical Office Force |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508378613 PECOS PAC ID: 9335481951 Enrollment ID: O20190501001903 |
News Archive
Nearly a billion years ago, bacteria evolved an insidious means of infecting their hosts - a syringe-like mechanism able to inject cells with stealthy hijacker molecules. These molecules, called virulence factors, play a sophisticated game of mimicry, imitating many of the cells' normal activities but ultimately co-opting them to serve the bacteria's needs.
More than 2 percent of all emergency department visits are now related to nontraumatic dental conditions, according to a study by researchers at Stanford University, the University of California-San Francisco, Truven Health Analytics and the federal Agency for Healthcare Research and Quality.
Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.
In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Julius Kolawole Adebisi, MD 401 S Main St, Suite C7, Alpharetta, GA 30009-1974 Ph: (678) 319-9901 | Dr Julius Kolawole Adebisi, MD 401 S Main St, Suite C7, Alpharetta, GA 30009-1974 Ph: (678) 319-9901 |
News Archive
Nearly a billion years ago, bacteria evolved an insidious means of infecting their hosts - a syringe-like mechanism able to inject cells with stealthy hijacker molecules. These molecules, called virulence factors, play a sophisticated game of mimicry, imitating many of the cells' normal activities but ultimately co-opting them to serve the bacteria's needs.
More than 2 percent of all emergency department visits are now related to nontraumatic dental conditions, according to a study by researchers at Stanford University, the University of California-San Francisco, Truven Health Analytics and the federal Agency for Healthcare Research and Quality.
Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.
In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
› Verified 9 days ago